Aflunov®: A vaccine tailored for pre-pandemic and pandemic approaches against influenza

Expert Opinion on Biological Therapy

Volumn 13, Issue 1, 2013, Pages 121-135

  Del Giudice, Giuseppe ^a   Fragapane, Elena ^a   Della Cioppa, Giovanni ^a   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Aflunov ; Influenza; MF59 ; Vaccine

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHEMA; FEASIBILITY STUDY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFLUENZA VIRUS A H5N1; NONHUMAN; PAIN; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SWELLING;

ADULT; AGED; CHILD; CLINICAL TRIALS AS TOPIC; FEASIBILITY STUDIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

AVES;

EID: 84870876997     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.748030     Document Type: Article

References (75)

1. Deng G, Li Z, Tian G, et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci USA 2004;101:10452-7
2. Available from: Http://www.who.int/influenza/human-animal-interface/EN- GIP-20120810Cumulative NumberH5N1cases.pdf
3. Li C, Hatta M, Nidom CA, et al. Reassortment between avian H5N1 and H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci USA 2010;107:4687-92
4. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012;486:420-8
5. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012;336:1534-41
6. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012;336:1541-7
7. Available from: Http://www.who.int/influenza/surveillance-monitoring/ updates/2012-08-17-influenza-global-circulation.pdf
8. Gillim-Ross L, Subbarao K. Emerging respiratory viruses: Challenges and vaccine strategies. Clin Microbiol Rev 2006;19:614-36
9. Girard MP, Katz JM, Pervikov Y, et al. Report of the 7th meeting on Evaluation of pandemic influenza vaccines in clinical trials. World Health Organization; Geneva: 2011
10. Stohr K. Vaccinate before the next pandemic? Nature 2010;465:161
11. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43
12. Podda A. The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80
13. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51
14. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis 2005;191:1210-15
15. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687-93
16. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009;106:7962-7
17. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008;359:1631-3
18. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 2009;27:6959-65
19. Black S, Della Cioppa G, Malfroot A, et al. Safety of MF59-adjuvanted versus non-adjuvanted vaccines in children and adolescents: An integrated analysis. Vaccine 2010;28:7331-6
20. Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008;26:3209-22
21. Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011;7:539-48
22. Cristiani C, Tucconi M, Pepe P, et al. Safety of MF59 adjuvanted vaccine for pandemic influenza: Results of the vaccination campaign in an Italian health district. Vaccine 2011;29:3443-8
23. Parretta E, Ianniello B, Ferrazin F, et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011;29:3708-13
24. Van Puijenbroek EP, van Grootheest AC. Monitoring adverse events of vaccines against Mexican flu. Int J Risk Saf Med 2011;23:81-7
25. Heikkinen T, Young J, Van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: A comparative cohort study. Am J Obstet Gynecol 2012;207(3):177; e1-8
26. Tsai T, Kyaw MH, Novicki D, et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy - a retrospective analysis. Vaccine 2010;28:1877-80
27. Alberini I, Del Tordello E, Fasolo A, et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009;27:5998-6003
28. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008;197:667-75
29. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted. H5N1 vaccine induces immunologica memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009;6:e4364
30. Fragapane E, Gasparini R, Schioppa F, et al. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 2010;17:1817-19
31. Vesikari T, Forsten A, Herbinger KH, et al. Safety and immunogenicity of an MF59-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012;30:1388-96
32. Beran J, Abdel-Messih IA, Raupachova J, et al. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week intervals between first and second doses. Clin Ther 2010;32:2186-97
33. Lopez P, Caicedo Y, Sierra A, et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: A phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J Infect Dis 2011;203:1719-28
34. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009;106:3877-82
35. Del Giudice G, Rappuoli R. Novel strategies for improved vaccines for the elderly: The example of influenza. In: Thiel A, editor. Immunosenescence, Birkhaeuser advances in infectious diseases. Springer; Basel: 2012. p. 201-227
36. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol 2012;176(6):527-33
37. Maue AC, Yager EJ, Swain SL, et al. T-cell immunosenescence: Lessons learned from mouse models of aging. Trends Immunol 2009;30:301-5
38. Gioia C, Castilletti C, Tempestilli M, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008;14:121-8
39. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-abalysis. Lancet 2011;378:1917-30
40. Khandaker G, Dierig A, Rashid H, et al. Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respir Viruses 2011;5:148-56
41. Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008;2:CD004879
42. Centers for Disease Control and Prevention (CDC). Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States. Morb Mortal Wkly Rep 2012;61:237-41
43. Available from: Http://www.cidrap.umn. edu/cidrap/content/influenza/ general/news/aug1712variant.html
44. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-71
45. Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (Fluad-) in children: Pafety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5
46. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365:1406-16
47. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011;30:1081-5
48. Wilkinson TM, Li KF, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18:274-80
49. Vesikari T, Karvonen A, Tilman S, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 vaccine from infancy to adolescence. Pediatrics 2010;126:e762-70
50. Vesikari T, Forsten A, Borkowski A, et al. Homologous and heterologous antibody responses to a one-year booster dose of an MF59-adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 2012;8:921-8
51. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43:1135-42
52. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/204 (H5N1) vaccine: Phase I randomized trial. Lancet 2007;367:1657-64
53. Khurana S, Chearwae W, Castellino F, et al. MF59-adjuvanted vaccines expand antibody repertoires targeting protective sites of pandemic H5N1 influenza virus. Sci Transl Med 2010;2:15ra5
54. Khurana S, Suguitan A Jr, Rivera Y, et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and siagnostic tools. PLoS Med 2009;6:e1000049-doi:10.371
55. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza viruses. Sci Transl Med 2011;3:85ra48
56. Meier S, Bel M, L'huillier A, H1N1 Epidemiology Study Group of Geneva. Antibody response to natural influenza A/H1N1/09 disease of following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011;29:3548-57
57. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 2011;63:1062-7
58. Soonawala D, Rimmelzwaan GF, Gelink LB, et al. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011;6:e16496
59. Esposito S, Tagliaferri L, Daleno C, et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011;29:1677-82
60. Paschke R, Pollok M, Geiger H, et al. Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in renal transplant recipients. J Prev Med Hyg 2003;44:79-84
61. Esposito S, Meregalli E, Daleno C, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza/ AH1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011;26:2018-24
62. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: A review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009;9:1057-71
63. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved acquired immunity. Vaccine 2011;29:2461-73
64. Caproni E, Tritto E, Cortese M, et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 2012;188:3088-98
65. Rahier JF, Papay P, Salleron J, European Crohn's and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456-62
66. Nohynek H, Jokinen J, Partinen M, et al. AS03-adjuvanted A/H1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536
67. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7:e33723
68. Tsai TF, Crucitti A, Nacci P, et al. Exploration of clinical trials and pharmacovigilance databases of MF59-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011;43:702-6
69. Dormitzer PR. Cell culture-derived influenza vaccines. In: Rappuoli R, Del Giudice G, editors. Influenza vaccines for the future. 2nd edition. Birkhaeuser advances in infectious diseases Springer; Basel: 2011. p. 293-312
70. Kapteyn JC, Porre AM, de Rond EJ, et al. HPLC-based quantification of haemagglutinin in the production of eggand MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009;27:1468-77
71. Verity EE, Camuglia S, Agius CT, et al. Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA. Influenza Other Respir Viruses 2011;6:101-9
72. Rappuoli R, Dormitzer PR. Influenza: Option to improve pandemic preparation. Science 2012;336:1531-3
73. Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v. J Infect Dis 2012; doi: 10.1093/infdis/jis500
74. Anthony SJ, St Leger JA, Pugliares K, et al. Emergence of fatal avian influenza in New England harbor seals. MBio 2012;3:pii e00166-12
75. Czajka H, Unal S, Ulusoy S, et al. A phase II, randomized clinical trial to demonstrate non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg 2012;53; In press